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ABSTRACT
PeutzeJeghers syndrome (PJS, MIM175200) is an
autosomal dominant condition defined by the
development of characteristic polyps throughout the
gastrointestinal tract and mucocutaneous pigmentation.
The majority of patients that meet the clinical diagnostic
criteria have a causative mutation in the STK11 gene,
which is located at 19p13.3. The cancer risks in this
condition are substantial, particularly for breast and
gastrointestinal cancer, although ascertainment and
publication bias may have led to overestimates in some
publications. Current surveillance protocols are
controversial and not evidence-based, due to the relative
rarity of the condition. Initially, endoscopies are more
likely to be done to detect polyps that may be a risk for
future intussusception or obstruction rather than
cancers, but surveillance for the various cancers for
which these patients are susceptible is an important part
of their later management.
This review assesses the current literature on the clinical
features and management of the condition,
genotypeephenotype studies, and suggested guidelines
for surveillance and management of individuals with PJS.
The proposed guidelines contained in this article have
been produced as a consensus statement on behalf of
a group of European experts who met in Mallorca in
2007 and who have produced guidelines on the clinical
management of Lynch syndrome and familial
adenomatous polyposis.
INTRODUCTION
Peutz-Jeghers syndrome (PJS) is an inherited poly-
posis syndrome in which multiple characteristic
polyps occur in the gastrointestinal tract, associ-
ated with mucocutaneous pigmentation, especially
of the vermilion border of the lips. It is inherited in
an autosomal dominant manner and is caused by
a germline mutation in the STK11 (LKB1) gene.
The proposed guidelines contained in this article
have been produced as a consensus statement on
behalf of a group of European experts who met in
Mallorca in 2007 and who have produced guidelines
on the clinical management of Lynch syndrome1
and familial adenomatous polyposis.2
PJS was initially documented by an English
physician3 who described twin sisters with oral
pigmentation, who were subsequently illustrated
by the surgeon J Hutchinson.4 One of the twins
died of an intussusception at age 20 years, and the
other of breast cancer at 52 years.
The eponym PeutzeJeghers syndrome was origi-
nally put forward in 1954 by Bruwer et al5 who based
the name on the work of Peutz,6 who described
a family with autosomal dominant inheritance of
gastrointestinal polyposis and pigmented mucous
membranes, and Jeghers7 8 who deﬁned the coexis-
tence of mucocutaneous pigmentation and gastroin-
testinal polyposis as a distinct clinical entity.
The incidence of this condition is estimated to be
between 1 in 50 000 to 1 in 200 000 live births.9
CLINICAL FEATURES
Mucocutaneous pigmented lesions are seen in
around 95% of patients and may be the ﬁrst clue to
an individual having PJS. Lesions tend to arise in
infancy, occurring around the mouth, nostrils,
perianal area, ﬁngers and toes, and the dorsal and
volar aspects of hands and feet. They may fade
after puberty but tend to persist in the buccal
mucosa. The histology of the pigmented macules is
increased melanin in basal cells, possibly due to an
inﬂammatory block to melanin migration from
melanocyte to keratinocyte. Lip freckling is not
unique to PJS and the differential diagnosis includes
Carney complex, a syndrome characterised by
spotty skin pigmentation and lentigines, most
commonly on the face, especially on the lips,
eyelids, conjunctiva and oral mucosa.10
The polyps seen in PJS have characteristic histo-
logical features, with a frond-like elongated epithe-
lial component and cystic gland dilatation extending
into the sub-mucosa or muscularis propria, and
arborising smooth muscle extending into polyp
fronds (in contrast to juvenile polyps, which have
a lamina propria lacking smooth muscle11). These
polyps are usually referred to as hamartomas, but
controversy surrounds their origin. It has been
suggested that the process underlying their devel-
opment may be mechanical, or that they may be
a result of stromal neoplasia.12 Small bowel polyps
may display the phenomenon of ‘pseudoinvasion’,
which may be mistaken for invasive carcinoma.13
The lack of cytological atypia among other features
can distinguish between true and pseudo invasion.
Polyps are found throughout the gastrointestinal
tract but most are in the small bowel (60e90%)14
and colon (50e64%). They may also be found at
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extra-intestinal sites such as the gallbladder, bronchi, bladder and
ureter.15 Gastrointestinal polyps may cause gastrointestinal
bleeding, anaemia and abdominal pain due to intussusception,
obstruction or infarction. Polyp-related symptoms usually arise in
childhood and are seen by the age of 10 years in 33% and by
20 years in 50%.
In a single individual, a clinical diagnosis of PJS may be made
when any ONE of the following is present16 17:
1. Two or more histologically conﬁrmed PJ polyps
2. Any number of PJ polyps detected in one individual who has
a family history of PJS in close relative(s)
3. Characteristic mucocutaneous pigmentation in an individual
who has a family history of PJS in close relative(s)
4. Any number of PJ polyps in an individual who also has
characteristic mucocutaneous pigmentation.
A study by Aretz et al17 correlated the diagnostic criteria for
PJS with STK11 mutation detection rates. Of the patients who
met the criteria for PJS, over 94% had a mutation detected (64%
point mutation, 30% deletions).
MOLECULAR GENETICS OF PJS
Initial linkage analysis localised the affected gene to chromo-
some 19p13.3.18 19 Further studies identiﬁed a gene encoding
a serineethreonine kinase, STK11 (LKB1).20 21 Hemminki et al20
cloned the gene and demonstrated mutations in the STK11 gene
in 11/12 (90%) PJS cases using direct sequencing of DNA and
mRNA. Recent studies which have searched for germline
mutations by both direct sequencing and also multiplex ligation
dependent probe ampliﬁcation (MLPA) demonstrate a detection
rate of germline mutations between 80% and 94%.17 22 23
Loss of heterozygosity at 19p13.3 seen in PJS polyps and
malignancy suggests that STK11 acts as a tumour suppressor
gene. The gene is more than 23 kb in length, and extends over
nine exons, encoding a 433 amino acid protein.
The function of STK11 is complex and still being clariﬁed.24
This serineethreonine kinase is expressed ubiquitously in adult
and fetal tissue. In brief, STK11 has been found to regulate
cellular proliferation via G1 cell-cycle arrest, WAF1 (a cyclin-
dependent kinase inhibitor) signalling25 26 and p53 mediated
apoptosis.27 It has an important role in cell polarity28 and
regulates the Wnt signalling pathway.29 It is also involved in cell
metabolism and energy homeostasis.30 It is an upstream regu-
lator of AMP activated protein kinase (AMPK), thereby regu-
lating the TSC pathway and acting as a negative regulator of the
mammalian target of rapamycin (mTOR) pathway.31 The
mTOR pathway is particularly important as it is a ﬁnal
common pathway that is also dysregulated by other hamar-
tomatous polyposis syndromes caused by germline PTEN,
BMPR1A and SMAD4 mutations.
Over-expression of COX-2 has been noted in PJS polyps and
cancers,32 and may present a therapeutic target for modulation
of polyp development.
A single family has shown linkage to 19q13.419 and some
evidence of linkage to 6p11-cen has also been demonstrated.33 In
addition, linkage studies of PJS families looking for a second PJS
locus34 35 suggested that in some the 19p13.3 locus was not
involved in PJS. This has raised the possibility of genetic
heterogeneity. A recent study36 examined the role of mutations
in the MYH11 gene in 25 STK11 mutation negative patients
with the PJS phenotype. One patient had a mutation
(c.5798_5799insC) in the MYH11 gene, although this mutation
was also found in apparently unaffected relative. Although
genetic heterogeneity has been questioned, no clear second
causative gene has been found for PJS cases without detectable
STK11 mutation. It is likely that with continued improvements
in genetic testing that mutation detection rates will improve
further, making genetic heterogeneity even less likely.
Genotypeephenotype correlation
A genotypeephenotype correlation has been sought in PJS.
Amos et al37 suggested individuals with missense mutations had
a later onset of symptoms than individuals with other muta-
tions in STK11. Schumacher et al38 suggested that in-frame
mutations in domains encoding protein and ATP binding and
catalysis (IeVIA) were rarely associated with cancer, missense
mutations in the C terminus and in the part of the gene
encoding protein domains for substrate recognition (VIBeVIII)
were more associated with malignancies, and patients with
breast carcinomas had predominantly truncating mutations.
Mehenni et al39 studied 49 PJS families with deﬁned mutations,
and found 32 cancers. They suggested that there was a higher
risk of cancer in cases with mutations in exon 6 of the STK11
gene. These studies, however, are small and it is difﬁcult to draw
ﬁrm conclusions from them. Most studies have been carried
out on western European populations but a study of Latin-
American PJS patients40 demonstrated mutations in exon 2
(c.350_351insT) and exon 6 (c.811_813delAG) of the STK11
gene.
In a larger series 240 PJS patients with STK11 mutations were
analysed. No difference was seen between individuals with
missense and truncating mutations, nor between familial and
sporadic cases although it was suggested that there was a higher
risk of cancer in individuals with mutations in exon 3 of the
gene. Hearle et al41 continued this study, analysing a total of 419
PJS patients, 297 with documented mutations. They found that
the type and site of mutation did not inﬂuence cancer risk.
In conclusion, no clear genotypeephenotype correlation has
been demonstrated in PJS, and no clear differences found
between cases with STK11 mutation and in those in whom no
mutation has been detected.
CANCER RISK
How cancer arises in PJS and the role of the PJS polyp in cancer
development remain controversial. It has been proposed that
a unique hamartomaeadenomaecarcinoma pathway42 exists.
This hypothesis is supported by the ﬁnding of adenomatous foci
within PJS polyps and also by the description of cancer arising
within PJS polyps.43 Others have proposed that the PJS polyps
have no malignant potential. Malignant transformation within
a PJS polyp is only seen as a rare event supporting this
hypothesis.44 In addition PJS polyps have been shown to be
polyclonal (and therefore unlikely to have malignant potential)
and it is suggested that the ‘PJS polyp’ may actually represent
a form of abnormal mucosal prolapse,44 caused by changes in
cellular polarity induced by mutation in the STK11 gene, rather
than a true hamartoma. If PJS polyps have no malignant
potential it would imply that cancer arises on a background of
mucosal instability, presumably through conventional
neoplastic pathways. Whether this pathway is accelerated is an
intriguing question which has yet to be answered. Certainly the
fact that only one of the 17 colorectal cancers seen in the largest
series41 was detected at surveillance raises the possibility of an
accelerated pathway (provided that patients were under
surveillance and compliance was adequate). Further research in
this area is required to clarify these issues.
Based on epidemiological and molecular genetic studies,45 it is
now widely accepted that there is an increased risk of many
cancers in PJS. Multiple single cohort studies have been carried
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out by individual groups14 38 46e52 which make up the bulk of
the literature. It is difﬁcult to come to any ﬁrm conclusions from
these relatively small studies, which are likely to be subject to
both ascertainment and publication bias, thereby potentially
inﬂating the cancer risk in PJS. A meta-analysis has been
performed by Giardiello et al, assessing 210 patients from six
studies.53 A study by Lim et al54 was subsequently continued by
Hearle et al41 to produce a cohort of 419 patients with PJS. These
studies by Giardiello and Hearle offer the most comprehensive
data for cancer risk and their main ﬁndings are summarised in
tables 1 and 2.
Hearle et al41 examined the incidence of cancer in 419 indi-
viduals with PeutzeJeghers syndrome, 297 of which had docu-
mented STK11 mutations. Ninety-six (23%) developed cancer,
the risks of which stratiﬁed by age are shown in table 1. Giar-
diello et al53 reviewed 210 PJS cases from six publications: the
relative risks of cancer of different sites are shown in table 2.
From these studies it can be seen that luminal gastrointestinal
cancers and breast cancer are the most common cancers, followed
by pancreatic cancer. It is striking in the Hearle study how risk
increases rapidly after the age of 50 for all cancers, a fact not
taken into consideration in most current surveillance protocols.
Mehenni et al55 recently examined the survival of 149 patients
(76 male, 73 female) all of whom had a documented STK11
mutation (table 3). This study differs from those above in that
only one case of breast cancer was observed. The reason for this
discrepancy is not clear. Otherwise the predominance of luminal
gastrointestinal cancer (especially colorectal) and the rapid
increase in cancer risk after the age of 50 years are conﬁrmed.
The observation of a rare sex cord tumour in PJS is important.
Young et al56 carried out a review of 74 sex cord ovarian tumours
with annular tubules (SCTAT), of stromal origin. Of these, 27
were in individuals with PJS, and all were multifocal, bilateral,
very small, benign and calciﬁed. They could develop in young
children, the youngest diagnosed at 4 years of age. Twelve
affected individuals had hyper-oestrogen syndrome; four had
adenoma malignum of the cervix of which two were fatal,
diagnosed at 23 years and 36 years of age.
Song et al57 described the case of a 41-year-old woman with
PJS who had multiple genital tract tumours and breast cancer;
their literature review found that 36% patients with SCTAT
have PJS, and SCTAT is usually benign and multifocal. Bilateral
malignant ovarian sex cord tumour was described in a 47-year-
old woman with PJS presenting with an abnormal cervical
smear58 and it was suggested that the hyper-oestrogenism
caused by sex cord tumours could induce cervical adenoma
malignum. This has a poor prognosis in general; of 10 cases
reviewed by Srivatsa et al,59 eight died, only one survived longer
than 5 years. One case of gonadoblastoma was described in a 34-
year-old PJS patient.60 Large-cell calcifying Sertoli cell tumours
of the testis can also develop, usually in pre-pubescent boys,
leading to gynaecomastia because of hormonal imbalance caused
by the neoplasm.61
Dozois et al62 reviewed 115 reported cases of PJS in females
from the literature. Of these 16/115 had ovarian tumours diag-
nosed at ages 4.5 to 60 years. There were ﬁve granulosa cell
tumours, ﬁve cystadenomas, four non-neoplastic cysts, one
Brenner tumour, one dysgerminoma, and two with undeter-
mined diagnoses.
Von Herbay63 reported a case of bronchoalveolar cancer of
mucinous type in a 22-year-old male with PJS, hypothesising
that it may represent a PJS associated cancer.
CLINICAL MANAGEMENT
Surveillance
Surveillance protocols in PJS have two main purposes. One is to
detect sizeable gastroenterological polyps which could cause
intussusception/obstruction or bleeding/anaemia. The other is
the detection of cancer at an early stage. The indication for
screening is therefore age dependent: polyp-related complica-
tions may arise in childhood, whereas the cancer risk largely
pertains to the adult population.
Although most authorities agree that surveillance of some sort
is warranted in patients with PJS, there is no consensus as to
what organs should be monitored, with what frequency and
when to start.
In order to carry out a comprehensive review of the literature
a systematic review of the screening evidence was carried out.
SYSTEMATIC REVIEW
Method
A systematic review of the available literature was carried out
using the Ovid Medline 1950 to current; the Ovid EMBASE 1980
to current; Ovid OLDMEDLINE; Cochrane Database of
Systematic Reviews and Pubmed.
Table 1 Cumulative cancer risk by site and age in PeutzeJeghers syndrome patients (from Hearle et al41)
Type of cancer
Cancer risk by age % (95% CI)
20 years 30 years 40 years 50 years 60 years 70 years
All cancers 2 (0.8 to to 4) 5 (3 to 8) 17 (13 to 23) 31 (24 to 39) 60 (50 to 71) 85 (68 to 96)
Gastrointestinal d 1 (0.4 to 3) 9 (5 to 14) 15 (10 to 22) 33 (23 to 45) 57 (39 to 76)
Breast (female) d d 8 (4 to 17) 13 (7 to 24) 31 (18 to 50) 45 (27 to 68)
Gynaecological d 1 (0.4 to 6) 3 (0.9 to 9) 8 (4 to 19) 18 (9 to 34) 18 (9 to 34)
Pancreas d d 3 (1 to 7) 5 (2 to 10) 7 (3 to 16) 11 (5 to 24)
Lung
Male d d 1 (0.1 to 6) 4 (1 to 11) 13 (6 to 28) 17 (8 to 36)
Female d d 1 (0.1 to 6) d d d
Table 2 Risk ratios, frequencies and ages of onset of PeutzeJeghers
syndrome cancers by site (from Giardiello et al53
Site Risk ratio (95% CI) Frequency (%)
Mean age
(years)
Age range
(years)
Oesophagus 57 (2.5 to 557) 0.5 67
Stomach 213 (96 to 368) 29.0 30.1 10e61
Small bowel 520 (220 to 1306) 13 41.7 21e84
Colon 84 (47 to 137) 39 45.8 27e71
Pancreas 132 (44 to 261) 36 40.8 16e60
Lung 17 (5.4 to 39) 15
Testis 4.5 (0.12 to 25) 9 8.6 3e20
Breast 15.2 (7.6 to 27) 54 37.0 9e48
Uterus 16 (1.9 to 56) 9
Ovary 27 (7.3 to 68) 21 28.0 4e57
Cervix 1.5 (0.31 to 4.4) 10 34.3 23e54
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Seperate search strategies were carried out with the MESH
search term ‘PeutzeJeghers Syndrome’ and ‘screening’. Searches
were combined with the AND operator.
All papers identiﬁed had their bibliography searched manually
to identify further papers of interest. A separate literature search
was carried out for therapeutic modalities using the MESH
search terms ‘PeutzeJeghers Syndrome’ and ‘therapy’.
The strength of evidence was classiﬁed according to the north
of England evidence-based guidelines development project64
(see table 4).
Inclusion and exclusion criteria
All articles discussing PeutzeJeghers syndrome mentioning
screening or surveillance were retrieved. For the therapy search,
all articles discussing PJS mentioning any therapeutic aspect
were retrieved. Acceptable article types retrieved were retro-
spective cohort studies, case reports, randomised controlled trials
and caseecontrol studies up to May 2009. Only English
language articles were retrieved and all articles were reviewed
independently for suitability (see ﬁgure 1).
Results
Screening
A total of 1254 papers were identiﬁed (Medline¼73,
Embase¼152, Cochrane¼0, OLDMedline¼0, Pubmed¼1029), of
which 12 met the criteria. Manual examination of the bibliog-
raphy of each paper found three additional papers that met the
criteria, giving a total of 15. Figure 1 shows the QUORUM
ﬂowchart for this search. Table 5 summarises the key recom-
mendations of each of the papers retrieved.
Therapy
A total of 286 papers were identiﬁed (Medline¼26, Embase¼9,
Cochrane¼0, OLDMedline¼0, Pubmed¼251). All 286 met the
criteria and were carried forward. Because of space constraints,
these papers are not listed in this review.
Surveillance recommendations
Question: What is the role of surveillance endoscopic examination of
the gastrointestinal tract?
One role for surveillance endoscopy is the detection of cancer.
Giardiello et al53 found a range of age from 27 to 71 years for
colorectal cancer diagnosis in PJS, with an overall risk of 39%,
the majority of which were in males. Hearle et al41 found that
colorectal cancer was the most common luminal gastrointestinal
cancer (17/40). The risk of colorectal cancer was 3%, 5%, 15%
and 39% at ages 40, 50, 60 and 70 years, respectively. Although
there was a male preponderance, this was not statistically
signiﬁcant. In this large series only one case of sigmoid cancer
was detected during surveillance.
Upper gastrointestinal (GI) cancers are less common. Gastric
cancer is far more common than oesophageal53 and the average
age of stomach cancer diagnosis was 30 years. Although very
rare, upper GI cancer has been reported during the ﬁrst and
second decades of life.53
The other indication for surveillance is the detection of large
polyps allowing early therapy and the prevention of polyp related
symptoms. There are sparse data regarding this. In a study from
a single institution reporting outcomes from gastrointestinal
surveillance, of 28 patients who had undergone one or more
surveillance endoscopies by the age of 18 years, 17 were found to
have developed signiﬁcant gastroduodenal or colonic polyps.79
Thirty-nine colonic polyps and 20 gastroduodenal polyps larger
than 1 cmwere detected in these patients; the largest lesions were
a 6 cm colonic polyp and an 8 cm gastric polyp.
The same series79 demonstrated that colonoscopic and upper
GI tract surveillance is safe. During 786 surveillance examina-
tions and over 1500 polypectomies, there were only two cases of
perforation (both following resection of polyps larger than 2 cm)
and no post-polypectomy bleeding was observed.
Dunlop et al68 recommended screening intervals of every
3 years for upper and lower GI endoscopy, beginning at age 18.
Hemminki et al65 recommended screening start at age 18, with
upper and lower GI endoscopy being performed at 2e5 year
intervals. Giardiello et al9 recommended a baseline upper GI
endoscopy at the age of 8 years and every 2e3 years thereafter if
polyps were detected. If no polyps are detected they recommend
further surveillance upper GI endoscopy from the age of
18 years, with colonoscopic surveillance also starting at this age.
Some authors advocate not starting screening at all until
age 18. We suggest starting at 8 years to pick up those with
polyps at that stage to prevent problems in late childhood/early
adolescence, which is when most obstructions occur. Data is
lacking on the rate of polyp progression, but those with no
polyps aged 8 years will still have follow-up, and be investigated
if symptomatic/anaemic. There is a paucity of evidence to
support recommendations here; however, we feel that this
strikes a balance between preventing polyp complications and
over-investigating children.
Table 3 Frequency of cancer in PeutzeJeghers
syndrome (Mehenni et al55)
Cancer site Cancer frequency
Gastro-oesophageal 6/149
Small bowel 4/149
Colorectal 11/149
Pancreatic d
Breast 1/149
Gynaecological 7/149
Lung d
Male reproductive d
Thyroid d
Hepatobiliary 1/149
Head and neck 1/149
Other d
Table 4 Categories of evidence and grading of recommendations
Category of evidence Grading of recommendation
Meta-analysis of randomised controlled trial Ia A
Randomised controlled trial Ib A
Well designed controlled study without randomisation IIa B
Well designed quasi-experimental study IIb B
Non-experimental descriptive study III B
Expert opinion IV C
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Conclusion: A baseline colonoscopy and upper GI endoscopy
(OGD) is indicated at age 8 years. In those in whom signiﬁcant polyps
are detected these should be repeated every 3 years. In those in whom
there are no signiﬁcant polyps at baseline endoscopy, routine surveil-
lance is repeated at age 18, or sooner should symptoms arise, and then
three yearly. We recommend that after the age of 50 years the frequency
is increased to every 1e2 years due to the rapid increase in cancer risk
at this age. There is, however, no evidence of beneﬁt (Level of
evidence: III, Grade of recommendation: C)
Question How and when should small bowel surveillance be
performed in PJS?
Small bowel surveillance for polyps allows polypectomy
before symptoms develop or obstruction occurs. A variety of
investigations can be used.
Several studies80 81 have compared barium follow-through and
capsule endoscopy. Two studies in adult patients found that
video capsule endoscopy (VCE) has a greater sensitivity in
detecting small bowel polyps. The study size was small in both
studies. A prospective study has been performed comparing
barium follow-through (BaFT) and VCE in paediatric patients
with PJS.82 No signiﬁcant difference was found in detection
rates of polyps >1 cm but VCE detected more polyps<1 cm and
also was much better tolerated. Many centres now use VCE,
since it appears at least as accurate as barium follow through, is
preferred by patients and reduces radiation exposure.
There are some early data on the use of magnetic resonance
enterography (MRE) assessment of the small bowel in patients
with PJS. Kurugoglu et al83 compared barium follow-through
with ultrasound and MRE. They found that polyps were
detected equally with contrast studies and MRE. Caspari et al84
compared VCE with MRE and observed that VCE was superior
at detecting small polyps. Polyps of 15 mm and above were
detected equally with both modalities and location of polyps
and determination of their exact sizes was more accurate with
MRE. Further studies to assess the utility of MRE are required.
There are no data to support the use of double-balloon
enteroscopy as a method of small bowel surveillance in PJS. It is
a prolonged, very invasive procedure and does not guarantee
visualisation of the entire small bowel, especially in those who
have undergone previous abdominal surgery. Although there are
some reports of its use in PJS these are in the setting of therapy
in patients with intussusception or prophylactically in patients
who have had polyps detected by other means.79
The main indication for surveillance of the small bowel is the
prevention of intussusception and the need for emergency
laparotomy. There are limited data to guide when to start
surveillance of the small bowel. A survey of adults with PJS70
found that by the age of 18 years, 23/34 (68%) of adults had
undergone laparotomy, 70% of which were performed as an
emergency. By the age of 10 years, 30% had required a lapa-
rotomy. In order to reduce the likelihood of developing intestinal
obstruction, the study recommended that asymptomatic chil-
dren start small bowel screening at the age of 8 years. A recent
review of gastrointestinal surveillance from a single institution
found that no patients enrolled on the programme required
emergency surgery for obstruction or intussusception during 683
patient years follow-up.79
Conclusion: Small bowel screening using video capsule endoscopy
(VCE) should be performed every 3 years if polyps are found at the
initial examination, from age 8 years, or earlier if the patient is
symptomatic. If few or no polyps are found at the initial examination,
screening should commence again at the age of 18. Magnetic resonance
enterography (MRE) and barium follow-through (BaFT) are reason-
able alternatives in adult patients but BaFT is not favoured in children
due to radiation exposure. (Level of evidence: III, Grade of
recommendation: B)
Question: What is the best method of breast cancer surveillance in
PJS?
The earliest documented case of breast cancer in PJS is
19 years, and clearly the breast cancer risk (cumulative risk
Figure 1 QUORUM diagram for screening evidence
review.
Literature search performed 
Medline = 73 
EMBASE = 152 
OLDMedline = 0 
Cochrane = 0 
PubMed = 1029 
Total n = 1254
Studies retrieved for more 
detailed evaluation 
n = 85 
Bibliographies of studies with 
relevant, useful information 
examined 
n = 12 
Final studies gathered 
n = 15 
Studies discarded for non-
relevance
n = 1169 
Studies discarded for non-
relevance
n = 73 
Gut 2010;59:975e986. doi:10.1136/gut.2009.198499 979
Guidelines
 group.bmj.com on March 30, 2011 - Published by gut.bmj.comDownloaded from 
Ta
bl
e
5
S
ys
te
m
at
ic
re
vi
ew
of
su
rv
ei
lla
nc
e
ev
id
en
ce
A
ut
ho
r,
ye
ar
R
ef
S
tu
dy
ty
pe
U
G
I
tr
ac
t
LG
I
tr
ac
t
P
an
cr
ea
s
B
re
as
t
R
ep
ro
du
ct
iv
e
Li
m
it
at
io
ns
of
st
ud
y
H
em
m
in
ki
19
99
65
Li
te
ra
tu
re
re
vi
ew
an
d
co
ho
rt
st
ud
y
of
PJ
S
pa
tie
nt
s
A
nn
ua
l
ha
em
og
lo
bi
n
co
nc
en
tr
at
io
n
O
G
D
ev
er
y
2
ye
ar
s
S
m
al
l
bo
w
el
st
ud
y/
en
te
ro
sc
op
y
ev
er
y
2
ye
ar
s
C
ol
on
os
co
py
ev
er
y
2
ye
ar
s
A
bd
om
in
al
ul
tr
as
ou
nd
ye
ar
ly
M
am
m
og
ra
ph
y
ev
er
y
2
ye
ar
s
fr
om
ag
e
35
,
an
nu
al
ly
af
te
r
ag
e
50
Ye
ar
ly
br
ea
st
ex
am
in
at
io
n
B
ur
t
20
00
66
Li
te
ra
tu
re
re
vi
ew
e
C
ol
on
os
co
py
,
be
gi
nn
in
g
at
sy
m
pt
om
s
or
la
te
te
en
s,
at
le
as
t
ev
er
y
3
ye
ar
s
e
e
W
om
en
e
pe
lv
ic
ex
am
,
tr
an
sv
ag
in
al
ul
tr
as
ou
nd
an
d
sm
ea
r
an
nu
al
ly
M
en
e
te
st
ic
ul
ar
ex
am
in
a-
tio
n
ye
ar
ly
,
ul
tr
as
ou
nd
if
sy
m
pt
om
at
ic
B
as
ed
pa
rt
ly
on
un
pu
bl
is
he
d
da
ta
;
un
kn
ow
n
sa
m
pl
e
si
ze
M
cG
ra
th
20
01
67
Li
te
ra
tu
re
re
vi
ew
A
nn
ua
l
ha
em
og
lo
bi
n
co
nc
en
tr
at
io
n
O
G
D
an
d
sm
al
l
bo
w
el
st
ud
y
(o
r
en
te
ro
sc
op
y)
ev
er
y
2
ye
ar
s
C
ol
on
os
co
py
ev
er
y
2
ye
ar
s
A
bd
om
in
al
ul
tr
as
ou
nd
ye
ar
ly
S
er
um
bi
lir
ub
in
co
nc
en
tr
a-
tio
n
ye
ar
ly
R
eg
ul
ar
br
ea
st
ex
am
in
at
io
n
M
am
m
og
ra
ph
y
ev
er
y
5
ye
ar
s
fr
om
25
e
45
ye
ar
s
th
en
ev
er
y
2
ye
ar
s
un
til
50
ye
ar
s
th
en
ye
ar
ly
d
B
as
ed
on
sp
or
ad
ic
co
lo
n
ca
nc
er
sc
re
en
in
g
pr
og
ra
m
m
e
D
un
lo
p
20
02
68
C
lin
ic
al
gu
id
el
in
es
an
d
re
vi
ew
of
ev
id
en
ce
O
G
D
ev
er
y
2e
3
ye
ar
s
fr
om
ag
e
25
C
ol
on
os
co
py
(o
r
fle
xi
bl
e
si
gm
oi
do
sc
op
y+
ba
riu
m
en
em
a)
ev
er
y
3
ye
ar
s
fr
om
ag
e
18
d
d
W
om
en
e
ye
ar
ly
pe
lv
ic
ul
tr
as
ou
nd
an
d
ce
rv
ic
al
sm
ea
rs
M
en
e
re
gu
la
r
te
st
ic
ul
ar
ex
am
in
at
io
n,
ul
tr
as
ou
nd
if
sy
m
pt
om
at
ic
Li
te
ra
tu
re
re
vi
ew
B
oa
rd
m
an
20
02
69
Li
te
ra
tu
re
R
ev
ie
w
O
G
D
an
d
sm
al
l
bo
w
el
fo
llo
w
th
ro
ug
h
ev
er
y
2
ye
ar
s
st
ar
tin
g
ag
e
10
C
ol
on
os
co
py
ev
er
y
2
ye
ar
s
fr
om
‘e
ar
ly
ad
ul
th
oo
d’
En
do
so
pi
c
or
tr
an
sa
bd
om
in
al
ul
tr
as
ou
nd
st
ar
tin
g
ag
e
30
M
am
m
og
ra
ph
y
ev
er
y
2
ye
ar
s
e
Li
te
ra
tu
re
re
vi
ew
H
in
ds
20
04
70
C
oh
or
t
st
ud
y
S
m
al
l
bo
w
el
st
ud
y
fr
om
ag
e
8,
ev
er
y
2
ye
ar
s
d
d
d
W
om
en
e
an
nu
al
pe
lv
ic
U
S
S
or
en
do
m
et
ria
l
bi
op
sy
st
ar
tin
g
at
ag
e
20
M
en
e
re
gu
la
r
se
lf
ex
am
Li
te
ra
tu
re
re
vi
ew
S
yn
ga
l
20
05
71
Li
te
ra
tu
re
re
vi
ew
O
G
D
an
d
sm
al
l
bo
w
el
fo
llo
w
-t
hr
ou
gh
ev
er
y
3e
5
ye
ar
s
C
ol
on
os
co
py
ev
er
y
3e
5
ye
ar
s
d
‘R
eg
ul
ar
’
br
ea
st
ex
am
in
at
io
n
‘R
eg
ul
ar
’
pe
lv
ic
an
d
ge
ni
ta
l
ex
am
in
at
io
n
Pa
ed
ia
tr
ic
po
pu
la
tio
n
on
ly
La
tc
hf
or
d
20
06
72
S
ys
te
m
at
ic
re
vi
ew
d
d
En
do
sc
op
ic
ul
tr
as
ou
nd
no
t
re
co
m
m
en
de
d
d
d
Li
te
ra
tu
re
re
vi
ew
M
cG
ar
rit
y
20
06
73
Li
te
ra
tu
re
re
vi
ew
O
G
D
an
d
sm
al
l
bo
w
el
st
ud
y
ev
er
y
2
ye
ar
s
fr
om
ag
e
10
C
ol
on
os
co
py
ev
er
y
2
ye
ar
s
fr
om
ag
e
25
En
do
sc
op
ic
ul
tr
as
ou
nd
ev
er
y
1e
2
ye
ar
s
fr
om
ag
e
30
Ye
ar
ly
br
ea
st
ex
am
in
at
io
n
an
d
tw
o
ye
ar
ly
m
am
m
og
ra
ph
y
fr
om
ag
e
20
d
O
nl
y
si
ng
le
ca
nc
er
G
ia
rd
ie
llo
20
06
9
Li
te
ra
tu
re
re
vi
ew
A
ge
8
e
ba
se
lin
e
O
G
D
an
d
sm
al
l
bo
w
el
se
rie
s
A
ge
18
e
O
G
D
an
d
sm
al
l
bo
w
el
st
ud
y
ev
er
y
2
ye
ar
s
C
ol
on
os
co
py
ev
er
y
2e
3
ye
ar
s
fr
om
ag
e
18
En
do
sc
op
ic
ul
tr
as
ou
nd
ev
er
y
1e
2
ye
ar
s
fr
om
ag
e
25
e
30
(C
T
+
C
A
-1
9.
9
al
te
rn
at
iv
e)
18
e
br
ea
st
ex
am
in
at
io
n
m
on
th
ly
25
e
br
ea
st
ex
am
in
at
io
n
ev
er
y
6
m
on
th
s
25
e
m
am
m
og
ra
ph
y
an
nu
al
ly
(M
R
I
al
te
rn
at
iv
e)
W
om
en
e
ye
ar
ly
pe
lv
ic
ul
tr
as
ou
nd
an
d
sm
ea
r
te
st
fr
om
ag
e
20
M
en
e
ye
ar
ly
te
st
ic
ul
ar
ex
am
in
at
io
n,
ul
tr
as
ou
nd
if
sy
m
pt
om
at
ic
Li
te
ra
tu
re
re
vi
ew
Ly
nc
h
20
07
74
Li
te
ra
tu
re
re
vi
ew
O
G
D
an
d
sm
al
l
bo
w
el
st
ud
y
ev
er
y
2e
3
ye
ar
s
C
ol
on
os
co
py
ev
er
y
2
ye
ar
s
fr
om
ag
e
25
d
A
nn
ua
l
br
ea
st
ex
am
;
tw
o
ye
ar
ly
m
am
m
og
ra
ph
y
W
om
en
e
21
e
sm
ea
r
te
st
an
nu
al
ly
25
e
tr
an
sv
ag
in
al
ul
tr
a-
so
un
d
an
d
se
ru
m
C
A
-1
25
an
nu
al
ly
M
en
e
te
st
ic
ul
ar
ex
am
fr
om
bi
rt
h
Li
te
ra
tu
re
re
vi
ew
C
on
tin
ue
d
980 Gut 2010;59:975e986. doi:10.1136/gut.2009.198499
Guidelines
 group.bmj.com on March 30, 2011 - Published by gut.bmj.comDownloaded from 
31e54% at age 60 years,41 53 usually ductal, sometimes lobular
with a mean age at diagnosis of 37 years (19e48), is signiﬁcant.
Breast cancer screening can be carried out via a variety of
methods including digital x-ray mammography, MR mammog-
raphy, ultrasound and self-examination. Radiological techniques
confer greater sensitivity than self-examination but the radiation
burden of repeated x-ray mammography is signiﬁcant. In addi-
tion, the sensitivity of mammography in younger patients with
dense breast tissue is reduced. In diagnostic use, ultrasound and
MR mammography both increase diagnostic accuracy in
a younger patient group with dense breast tissue compared to x-
ray mammography.85 However, MRI mammography is signiﬁ-
cantly superior to ultrasound in screening. A model developed to
assess cost effectiveness of breast cancer screening with
contrast-enhanced MRI in patients with germline BRCA1 and 2
mutations demonstrated that screening with MRI, alone or in
combination with x-ray mammography, is cost effective by
current standards compared with x-ray mammography alone.86
Although no breast screening techniques have been evaluated
speciﬁcally in patients with PJS, due to the fact that the risk is
approaching that of patients with BRCA mutations, it would
seem logical that the breast surveillance programme recom-
mended for BRCA mutation and other high risk patients be
utilised in PJS 87; namely annual MRI from age 25 years. These
guidelines recommend mammography in addition, because of
the high incidence of ductal carcinoma in situ (DCIS) associated
with BRCA mutations. There is currently no evidence of
increased incidence of DCIS in PJS.
MR mammography may not currently be widely available. It
is also more expensive than mammography and may not be
tolerated by some individuals. In this setting it may be reason-
able to offer supplemental ultrasound, especially in those with
dense breast tissue, although it is not recommended as
a screening modality.
Conclusion: Annual MRI/US should start at age 25e30 years,
with x-ray mammography being substituted after the age of 50. (Level
of evidence: IV, Grade of recommendation: C)
Question: Is pancreatic cancer surveillance useful in PJS?
The degree to which pancreatic cancer risk is elevated is
unclear. Hearle et al41 observed a cumulative risk of 7% at age 60,
which is at markedly less than 36% by 64 years observed by
Giardiello et al.53
Screening for pancreatic cancer is particularly difﬁcult and to
date there are no ﬁrm data that demonstrate clear beneﬁt even in
the setting of a higher risk of development of pancreatic cancer (eg,
hereditary pancreatitis). The sequence of the development of
pancreatic cancer is thought to be similar to that of the adeno-
maecarcinoma sequence in colorectal cancer. Initially, a pancreatic
intraepithelial neoplasia (PanIN) lesion (elongated mucin-pro-
ducing cells with little neoplasia) develops, leading through to
PanIN-lll lesions (carcinoma in situ). Although this model of
progression is widely accepted it has not been fully validated and
the natural history of PanIN, in terms of time to progression to
cancer, has not been established. In addition early lesions are not
radiologically detectable until the development of associated
secondary changes such as ﬁbrosis and retention cysts.72
Suggested screening regimes have included endoluminal
ultrasonography (sensitive), CT (not sensitive for detecting
small lesions especially PanIN) and endoscopic chol-
angiopancreatography (ERCP), with molecular analysis of
pancreatic secretions,88 speciﬁcally for k-RAS mutations (not
speciﬁc for cancer); p16/INK4A and p53 mutations (more
speciﬁc) and methylation analysis of the p16/INK4A promoter
(60% sensitivity, 90% speciﬁcity). However, in order to harvestTa
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these pancreatic secretions, ERCP must be used. The complica-
tions of ERCP are pancreatitis (6.7% incidence), which is severe
in 0.3%, and a mortality rate of 0.03% post-procedure. Magnetic
resonance cholangiopancreatography (MCRP) is a possible
alternative to the other modalities, but there is no evidence for
its routine use. It has been estimated that implementing
a surveillance programme in PJS would cost in excess of US$
350 000 per life saved, assuming that all cases of pancreatic
cancer diagnosed during the programme survived.72
Conclusion: Routine surveillance for pancreatic cancer in PJS
using current methods is not proven to be of beneﬁt and is not cost
effective. It should only be performed in the setting of a clinical research
study. (Evidence level: III, Grade of recommendation: B)
Question: Should surveillance for genital tract malignancies be
performed in PJS?
The increase in ovarian tumour risk is mainly not for
epithelial ovarian cancer but for SCTAT, which can occur in very
young children (2 and 4 years of age reported in the study by
Lim et al54) although the main risk appears to be in the fourth
and ﬁfth decades of life. Giardiello et al53 reported a 21% lifetime
risk of ovarian tumours, a risk of cervical cancer of 9% by
64 years (mean age at diagnosis 34 years) and 10% of uterine
cancer. The risks observed by Hearle and colleagues are lower.41
They observed nine gynaecological cancers (two uterine, two
ovarian and ﬁve cervical), with a risk of 1% at age 30 years, rising
to 18% at age 60 years.
Ovarian cancer screening is based on CA-125 levels and trans-
vaginal ultrasound scanning, and has been suggested at 6e12
monthly intervals in patients with PJS.77 However, as epithelial
ovarian cancer is not a speciﬁc risk, and there are no data on this
type of surveillance in PJS, this recommendation is not
supported by evidence. Furthermore, initial ﬁndings from the
UKCTOCS have recently been reported, assessing multimodal
screening (ultrasound and Ca-125) for ovarian cancer in a post-
menopausal cohort.89 The positive predictive value (PPV) was
poor: 43% for multimodal screening and only 5% for ultrasound.
In addition an effect on survival using multimodal screening has
not yet been demonstrated. The poor PPV observed reﬂects the
high prevalence of benign adnexal abnormalities. In PJS, the
ovarian tumours are SCTAT, and there is no clear evidence about
the effectiveness of any screening modality for this type of
tumour. In a younger cohort of PJS patients, it would be
a concern that there would be a higher prevalence of benign
pathology detected by screening and unnecessary surgical
intervention might be performed as a result.
Surveillance for endometrial cancer could be similar to that of
Lynch syndrome patients, with a 12-month interval being
recommended, from 35 years of age. Endometrial pipelle biopsy
sampling and trans-vaginal ultrasound are the recommended
screening modalities.90 However, the value of surveillance for
endometrial cancer in Lynch syndrome is unknown.1 Given that
most cases of sporadic endometrial cancer are detected at an
early stage and the risk of endometrial cancer in PJS is much
lower than in Lynch syndrome, it would be reasonable to argue
that endometrial surveillance is unnecessary and certainly has no
evidence to support its use.
Population cervical screening is widely practised and has been
shown to be effective in the reduction of cervical cancer and
associated mortality91 92 There are no studies that have speciﬁ-
cally addressed any means of surveillance for cervical cancer in
patients with PJS. It has been recommended on expert opinion
that patients with PJS undergo cervical smears as per population
screening programme but with a high index of suspicion for
adenoma malignum. This would mean a smear every 2e3 years
using the new technique of liquid-based cytology (LBC)91 from
age 21 to 25 years.
Testicular cancer surveillance is recommended on the basis of
expert opinion only. In a literature review all cancers detected
were Sertoli cell tumours and occurred at an average age of
9 years.53 Annual testicular examination47 93 is recommended
with ultrasound scanning reserved for patients where an
abnormality is found or precocious puberty develops.
Conclusion: There is no evidence to support routine screening for
genital tract malignancies in PJS. However, expert opinion advocates
regular screening consisting of 2e3 yearly cervical smears using liquid-
based cytology (LBC) from age 25 years, testicular examination and
testicular ultrasound in patients where an abnormality is detected at
examination. Routine surveillance for endometrial and ovarian cancers is
not recommended. (Evidence level: IV, Grade of recommendation: C)
Question: Are there any other malignant tumours that should be
part of a PJS surveillance programme?
Thyroid cancer may be slightly increased in PJS, and has been
reported at a young age (30 years)48 but screening for thyroid
cancer is not validated although clinical thyroid examination
could be included in regular clinical examinations of PJS
patients. Lung cancer is also increased, with a young age at
diagnosis (mean age at diagnosis 49 years),48 but screening for
this has not been advocated.
Conclusion: There is no evidence for screening of other malig-
nancies in PJS (Evidence level: IV, Grade of recommendation: C)
Therapy
Few options exist for the therapeutic management of PJS.
Surgical strategies are common with dealing with the sequelae
of PJS such as small bowel intussusception due to hamartoma-
tous polyps or resection of neoplastic lesions.
Question: Is endoscopic polypectomy of beneﬁt?
Endoscopic polypectomy is recommended at upper GI endos-
copy and colonoscopy to reduce cancer risk9 93 94 based on data
obtained from patients with a sporadic adenomatous polyp. As
themalignant potential of polyps in PJS is unknown, it is not clear
if endoscopic polypectomy alters cancers risk. Latchford et al79
found only six cases of atypia or dysplasia in over 1000 PJS polyps;
there were no polyps with adenomatous foci or malignant
change.79 The rarity of dysplasia and neoplasia argues against
a hamartomaeadenomaecarcinoma pathway and therefore it is
likely that polypectomy does not inﬂuence cancer risk.
The recent development of the double balloon enteroscope95
and the capsule endoscopy device95 have allowed direct visual-
isation of the small bowel, and in the case of the double balloon
enteroscope, resection of polyps via a standard snare polypectomy.
Intra-operative enteroscopy (IOE) has been also recom-
mended67 96 in any patient with PJS undergoing laparotomy, as
careful endoscopy via an enterotomy in the small bowel allows
identiﬁcation and removal of polyps found in the small bowel,
thus avoiding multiple enterotomies and the risk of short bowel
syndrome associated with resection. This technique allows
greater sensitivity in polyp detection than palpation and trans-
illumination (38% of polyps identiﬁed at IOE were not detected
by these methods,97 and removal of all detected polyps (‘clean
sweep’) reduced the re-laparotomy rate signiﬁcantly.98
It is likely that the main beneﬁt of polypectomy is to prevent
polyp-related complications rather than reduce cancer risk.
Prevention of anaemia and bleeding is difﬁcult to quantify but
certainly IOE has been shown to reduce the risk of further
operative polypectomy in the future.99
Conclusion: Endoscopic polypectomy reduces polyp-related
complications and risk of future operative polypectomy. If a laparotomy
982 Gut 2010;59:975e986. doi:10.1136/gut.2009.198499
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is performed on a patient with PJS, either as an emergency for
obstruction/intussusception, or electively for the removal of large or
symptomatic polyps which cannot be removed endoscopically, IOE and
‘clean sweep’ polypectomy should be undertaken (Evidence level: IIb,
Grade of recommendation: B)
Question: Does pharmacological prophylaxis exist for PJS
patients?
Lack of LKB1 kinase in PJS and many sporadic cancers drives
cell growth and proliferation by inappropriate activation of
mTOR protein kinase cascade. Recent animal-based studies have
focused upon inhibitors of the mTOR pathway, speciﬁcally
rapamycin.100 Lkb16 mice were treated with rapamycin 2 mg/
kg/day and killed mice were examined for polyp burden. It was
found that tumour burden decreased signiﬁcantly in the treat-
ment group, suggesting that rapamycin may have potential as
a therapeutic agent in patients with STK11 mutations. There is
a clinical trial (NCT00811590) under way in PJS patients of
everolimus (RAD001), which inhibits one of the complexes of
mTOR, mTORC1 but does not inhibit mTORC2. Some
companies also are trialling PI3-kinase, AKT and PDK1 inhibi-
tors, upstream regulators of mTOR.
The role of the pro-inﬂammatory cyclooxygenase pathway in
the pathogenesis of PJS polyps has been studied in a mouse
model by Udd et al.101 LKB16mice were treated with 1500 ppm
of celecoxib, a selective COX2 inhibitor. These mice were found
to have a 54% reduction in polyp burden. A very small clinical
trial within this study was carried out in six patients with
documented STK11mutations who were treated with 400 mg of
celecoxib daily for 6 months. In two patients gastric polyp
burden was reduced after treatment with celecoxib.
Metformin has been identiﬁed as a potential agent that could
slow the development of neoplasia in PJS. Using a PTEN-deﬁ-
cient mouse model, Huang et al102 demonstrated that activation
of the LKB1-AMPK pathway by metformin, phenformin or A-
769662 signiﬁcantly slowed tumour onset and identiﬁed the
potential of metformin in polyposis syndromes associated with
the dysregulation of LKB1 and PTEN.
Large cell calciﬁed Sertoli cell tumours (LCST) can lead to
gynaecomastia, which has been hypothesised to be due to an
alteration in inhibin regulation. A small study examined the use
of anastrozole, an aromatase inhibitor used for the treatment of
breast carcinoma61 to inhibit the clinical features of LCST and
found that oestradiol and inhibin levels decreased, suggesting
that it may have a role in this condition. However, as these
tumours have a malignant potential, bilateral orchidectomy is
still recommended as a curative procedure.67
Conclusion: There are a number of potentially promising agents
for reduction of polyp burden in PJS; however, none of these are
in routine clinical use (Evidence level: IIb, Grade of recommenda-
tion: B)
Question: Is there any treatment to ameliorate the mucocutaneous
pigmentation seen in PJS?
Although the mucocutaneous pigmentation seen in PJS may
fade with age, it can be disﬁguring and cause psychological
stress. The use of ﬁltered intense pulse light (IPL) with a 590 nm
cut-off ﬁlter was reported in a single case whereby it led to
a rapid improvement in the cosmetic appearance of the
lesions.103 Similar improvements have also been described with
Q-switched ruby laser104 105 and CO2-based lasers.106
Conclusion: Although there have been reports of success with
intense pulsed light and laser therapy, their use cannot be supported in
routine clinical practice. Its use should be reserved for cases with
signiﬁcant psychological morbidity related to pigmentation (Evidence
level: IV, Grade of recommendation: C)
DISCUSSION AND CONCLUSIONS
PeutzeJeghers syndrome is a clinically diverse disease entity,
with multiple neoplastic manifestations and a very high lifetime
risk of developing malignancy. The current evidence for
surveillance guidelines is weak due to the relative rarity of PJS
and the lack of data addressing effectiveness and outcomes from
surveillance in PJS.
Current surveillance guidelines are highly intensive. Several of
the surveillance modalities presented here are invasive and the
frequency at which they are carried out presents a signiﬁcant
burden for the PJS patient. Surveillance has two purposes in PJS
patients: ﬁrst, to reduce the polyp burden and the likelihood of
polyp related complications, particularly intussusception, in the
young PJS patient; and, second, cancer surveillance in the older PJS
patient. We have attempted to reﬂect this in our guidelines. The
main aim of surveillance in childhood should be reducing the risk
of intussusception. As such we have recommended that endo-
scopic examination is less frequent in this age group compared to
adult patients, where the main aim is detecting cancer at an early
stage. Recommendations on surveillance, therapy and clinical
management are summarised in boxes 1 and 2.
The lack of understanding regarding cancer development in
PJS makes the generation of surveillance guidelines problematic,
when one of the main aims is cancer detection/prevention.
Studies to clarify cancer development and the malignant
potential of PJS polyps are required and may have a signiﬁcant
impact on our current recommendations.
There is little research currently about potential biomarkers
for the identiﬁcation of early neoplasia, with the exception of
colorectal (faecal occult blood, faecal k-RAS) and pancreatic
lesions (k-RAS in pancreatic secretions), but these methods lack
sensitivity and speciﬁcity and have only been applied previously
to sporadic cancer. Radiological screening shows promise in
certain tumour types; however, tumours such as ovarian carci-
noma are difﬁcult to diagnose effectively by conventional
Box 1 Summary of recommendations for surveillance and
follow-up
General
Annual full blood count (FBC), Liver function testing (LFT)
Annual clinical examination
Genital tract
Annual examination and testicular examination from birth until
12 years
Testicular ultrasound if abnormalities detected at examination
Cervical smear with LBC three yearly from age 25 years
Gastrointestinal
Baseline OGD/colonoscopy age 8
Polyps detected, continue three yearly until 50 years
No polyps detected, repeat age 18 years, then three yearly
until 50 years
Colonoscopy 1e2 yearly after age 50 years
VCE every 3 years from age 8 years
Breast
Monthly self examination from age 18 years
Annual breast MRI from age 25e50, thereafter annual
mammographyLBC, liquid-based cytology; MRI, magnetic reso-
nance imaging; OGD, baseline colonoscopy and upper gastroin-
testinal endoscopy; VCE, video capsule endoscopy.
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radiological methods until they have progressed beyond an early,
pre-invasive stage.
Endoscopic polypectomy via upper GI endoscopy, colono-
scopy and double-balloon enteroscopy has demonstrated its
utility in reducing the need for future operative polypectomy
from the small bowel. Double-balloon enteroscopy, however, can
be a traumatic procedure and its use currently is limited to
therapy rather than diagnosis. The development of capsule
endoscopy has enhanced the diagnostic armamentarium avail-
able to the clinician and allows more thorough and regular
surveillance of the small bowel for polyposis.
The mTOR pathway shows signiﬁcant promise for modula-
tion or limitation of progression of PJS polyps; however, clinical
trials in this area are at a very early stage and involve some
agents, such as everolimus/sirolimus that carry a risk of signif-
icant systemic toxicity. Intervention in the COX2 pathway also
shows promise, although a very limited study has examined the
role of celecoxib which has now been associated with increases
in cardiovascular disease risk and therefore its long term use may
not be suitable in this group.
In conclusion, guidelines for PJS are largely formed via
consensus rather than a robust evidence base. Therapeutic inter-
ventions and surveillance modalities are expanding, but assess-
ment of these is challenging given the rarity of the condition.
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